SCHEMBL18838296

SCHEMBL18838296

O=C(NC1CC12CCNCC2)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 2/20 0.45
▸ HDAC1 Q13547 2/20 0.44
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ SCN9A Q15858 2/20 0.43
▸ FAAH O00519 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ IDO1 P14902 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ NCOR2 Q9Y618 1/20 0.42
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18860312 0.87 DDB1 (0.46) EZH2HDAC1DDB1CRBNHDAC3
SCHEMBL18838408 0.87 DDB1 (0.46) EZH2HDAC1DDB1CRBNHDAC3
SCHEMBL18838367 0.84 DDB1 (0.44) EZH2HDAC1DDB1CRBNMEN1
SCHEMBL18860231 0.79 P2RX7 (0.42) HDAC1SCN9AHDAC3HDAC2HDAC6
SCHEMBL21726744 0.79 P2RX7 (0.42) HDAC1SCN9AHDAC3HDAC2HDAC6
SCHEMBL18860223 0.79 SCN9A (0.49) EZH2HDAC1SCN9AHDAC6MEN1
SCHEMBL30479051 0.79 EZH2 (0.55) EZH2DDB1CRBNFAAHMEN1
SCHEMBL15653706 0.78 EPHX1 (0.34) SCN9AKMT2A
SCHEMBL1286815 0.78 KMT2A (0.55) SCN9AHDAC8KMT2A
SCHEMBL19995695 0.75 ALDH1A1 (0.49) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses AFASCI, INC. (US) 2018-11-01 — — US disclosed
EP-3340988-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES Afasci, Inc. (US) 2018-07-04 — — EP disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses CACNA1I, CACNA1G, CACNA1H EZH2 4818/4885HDAC1 1735/4885DDB1 4782/4885
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses CACNA1I, CACNA1G, CACNA1H EZH2 4818/4885HDAC1 1735/4885DDB1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback